Cargando…
Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
BACKGROUND: Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740341/ https://www.ncbi.nlm.nih.gov/pubmed/34996385 http://dx.doi.org/10.1186/s12883-021-02544-7 |
_version_ | 1784629293065699328 |
---|---|
author | Wu, Gang Jiang, Zhengli Pu, Yaling Chen, Shiyong Wang, Tingling Wang, Yajing Xu, Xiaoping Wang, Shanshan Jin, Minya Yao, Yangyang Liu, Yang Ke, Shaofa Liu, Suzhi |
author_facet | Wu, Gang Jiang, Zhengli Pu, Yaling Chen, Shiyong Wang, Tingling Wang, Yajing Xu, Xiaoping Wang, Shanshan Jin, Minya Yao, Yangyang Liu, Yang Ke, Shaofa Liu, Suzhi |
author_sort | Wu, Gang |
collection | PubMed |
description | BACKGROUND: Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson’s symptoms. METHODS: 50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson’s symptoms and the potential effects of medications on the serum SCFAs was analyzed. RESULTS: Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson’s Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid. CONCLUSIONS: Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-021-02544-7. |
format | Online Article Text |
id | pubmed-8740341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87403412022-01-07 Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Wu, Gang Jiang, Zhengli Pu, Yaling Chen, Shiyong Wang, Tingling Wang, Yajing Xu, Xiaoping Wang, Shanshan Jin, Minya Yao, Yangyang Liu, Yang Ke, Shaofa Liu, Suzhi BMC Neurol Research BACKGROUND: Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson’s symptoms. METHODS: 50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson’s symptoms and the potential effects of medications on the serum SCFAs was analyzed. RESULTS: Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson’s Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid. CONCLUSIONS: Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-021-02544-7. BioMed Central 2022-01-07 /pmc/articles/PMC8740341/ /pubmed/34996385 http://dx.doi.org/10.1186/s12883-021-02544-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wu, Gang Jiang, Zhengli Pu, Yaling Chen, Shiyong Wang, Tingling Wang, Yajing Xu, Xiaoping Wang, Shanshan Jin, Minya Yao, Yangyang Liu, Yang Ke, Shaofa Liu, Suzhi Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients |
title | Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients |
title_full | Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients |
title_fullStr | Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients |
title_full_unstemmed | Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients |
title_short | Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients |
title_sort | serum short-chain fatty acids and its correlation with motor and non-motor symptoms in parkinson’s disease patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740341/ https://www.ncbi.nlm.nih.gov/pubmed/34996385 http://dx.doi.org/10.1186/s12883-021-02544-7 |
work_keys_str_mv | AT wugang serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT jiangzhengli serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT puyaling serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT chenshiyong serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT wangtingling serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT wangyajing serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT xuxiaoping serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT wangshanshan serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT jinminya serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT yaoyangyang serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT liuyang serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT keshaofa serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients AT liusuzhi serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients |